Basic Information
| LncRNA/CircRNA Name | TUG1 |
| Synonyms | NA |
| Region | GRCh38_22:30969245-30979395 |
| Ensemble | ENSG00000253352 |
| Refseq | NR_002323 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Cisplatin | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | bladder cancer |
| ICD-0-3 | C67 |
| Methods | qPCR, Luciferase reporter assay, Western blot |
| Sample | bladder tissue,cell lines (5637, HT1376, J82, and T24) |
| Expression Pattern | up-regulated |
| Function Description | In this study, we found that TUG1 was upregulated in bladder cancer and the expression of TUG1 was positively and negatively correlated with CCND2 and miR-194-5p, respectively. MiR-194-5p expression was frequently decreased through promoter hypermethylation, while it was epigenetically increased following cisplatin and 5-aza-2??deoxycytidine (5-Aza-DC) treatment. |
| Pubmed ID | 30925453 |
| Year | 2019 |
| Title | lncRNA TUG1 Promotes Cisplatin Resistance by Regulating CCND2 via Epigenetically Silencing miR-194-5p in Bladder Cancer. |
External Links
| Links for TUG1 | GenBank HGNC NONCODE |
| Links for bladder cancer | OMIM COSMIC |